09/17/2024
5:20 PM | Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/17/2024
3:40 PM | Esposito Pamela (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024
5:31 PM | Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/26/2024
3:32 PM | Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024
3:25 PM | Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/22/2024
4:06 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/22/2024
3:15 PM | BAKER BROS. ADVISORS LP (Filed by)
Kymera Therapeutics (Subject)
| Form SC 13D/A | |
|
08/22/2024
3:03 PM | 667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
4:24 PM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/20/2024
3:31 PM | Kymera Therapeutics (Filer)
| Form 424B5 | |
08/07/2024
6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/07/2024
6:15 AM | Kymera Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/25/2024
5:12 PM | Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/23/2024
4:17 PM | Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/16/2024
5:00 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
3:28 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/15/2024
3:31 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/09/2024
4:15 PM | Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/09/2024
3:16 PM | Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/09/2024
3:18 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/28/2024
4:05 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2024
7:30 AM | Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Kymera Therapeutics (Issuer)
Morgan Leigh (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Kymera Therapeutics (Issuer)
MARAGANORE JOHN (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Hrustanovic Gorjan (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Kymera Therapeutics (Issuer)
Ridloff Elena (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:00 PM | Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2024
4:01 PM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/20/2024
7:30 AM | Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2024
5:01 PM | Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/13/2024
4:14 PM | Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/13/2024
4:15 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/12/2024
4:23 PM | Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/12/2024
4:24 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2024
5:36 PM | Horobin Joanna (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/07/2024
3:27 PM | Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/23/2024
4:22 PM | Chadwick Jeremy G (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/02/2024
6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/02/2024
6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Next opportunity for crypto millions (Ad) As we enter crypto's golden quarter (October-December), this coin is primed for takeoff.
The best part? Most investors haven't caught on yet.
This is your rare chance to be ahead of the curve.
 Click here to uncover the crypto that could redefine wealth in Q4. |
05/02/2024
6:15 AM | Kymera Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/24/2024
3:15 PM | Kymera Therapeutics (Filer)
| Form ARS | |
04/24/2024
3:06 PM | Kymera Therapeutics (Filer)
| Form DEF 14A | |
04/24/2024
3:10 PM | Kymera Therapeutics (Filer)
| Form DEFA14A | |
04/01/2024
7:53 AM | BAKER BROS. ADVISORS LP (Reporting)
Kymera Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
04/01/2024
7:56 AM | 667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/01/2024
7:57 AM | BAKER BROS. ADVISORS LP (Filed by)
Kymera Therapeutics (Subject)
| Form SC 13D | |
04/01/2024
6:00 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/15/2024
6:23 PM | Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/15/2024
3:30 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/14/2024
4:01 PM | Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/14/2024
4:02 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/13/2024
6:52 PM | Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/13/2024
6:53 PM | Atlas Venture Associates Opportunity I, L.P. (Reporting)
Atlas Venture Associates Opportunity I, LLC (Reporting)
ATLAS VENTURE ASSOCIATES X, L.P. (Reporting)
Atlas Venture Associates X, LLC (Reporting)
Atlas Venture Fund X, L.P. (Reporting)
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/13/2024
3:55 PM | Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/13/2024
3:55 PM | Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/12/2024
4:17 PM | Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
5:21 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
4:47 PM | Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/04/2024
4:50 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/29/2024
3:34 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/27/2024
3:22 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/22/2024
6:32 AM | Kymera Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/22/2024
6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/22/2024
6:16 AM | Kymera Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/21/2024
5:46 PM | Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
8:15 AM | Avoro Capital Advisors LLC (Filed by)
Kymera Therapeutics (Subject)
| Form SC 13G/A | |
02/12/2024
9:03 AM | Kymera Therapeutics (Subject)
PRICE T ROWE ASSOCIATES INC /MD/ (Filed by)
| Form SC 13G/A | |
02/12/2024
9:07 AM | Kymera Therapeutics (Subject)
PRICE T ROWE ASSOCIATES INC /MD/ (Filed by)
| Form SC 13G/A | |
02/09/2024
6:47 PM | Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/08/2024
9:21 AM | Kymera Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
| Form SC 13G/A | |
01/29/2024
2:26 PM | BlackRock Inc. (Filed by)
Kymera Therapeutics (Subject)
| Form SC 13G/A | |
01/23/2024
6:37 PM | Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/23/2024
3:19 PM | Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/23/2024
9:31 AM | Kymera Therapeutics (Subject)
STATE STREET CORP (Filed by)
| Form SC 13G/A | |
01/10/2024
3:52 PM | BAKER BROS. ADVISORS LP (Filed by)
Kymera Therapeutics (Subject)
| Form SC 13G/A | |
01/09/2024
3:45 PM | BIOTECHNOLOGY VALUE FUND L P (Filed by)
Kymera Therapeutics (Subject)
| Form SC 13D/A | |
01/09/2024
3:49 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/05/2024
4:15 PM | Chiniara Ellen (Reporting)
Kymera Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/05/2024
3:11 PM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/04/2024
3:01 PM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/04/2024
3:06 PM | Kymera Therapeutics (Filer)
| Form 424B5 | |
01/04/2024
8:29 AM | Chiniara Ellen (Reporting)
Kymera Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/04/2024
6:08 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/02/2024
4:43 PM | Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/06/2023
5:00 PM | Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/06/2023
5:07 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/02/2023
8:15 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/02/2023
6:10 AM | Kymera Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/02/2023
6:15 AM | Kymera Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
Next opportunity for crypto millions (Ad) As we enter crypto's golden quarter (October-December), this coin is primed for takeoff.
The best part? Most investors haven't caught on yet.
This is your rare chance to be ahead of the curve.
Click here to uncover the crypto that could redefine wealth in Q4. |
